receptor agonist (EC50
values are 0.4, 100 and >1000 nM for VPAC2
, respectively in a cAMP accumulation assay; IC50
values are 60, 8700 and >10000 nM for VPAC2
, respectively in a competition binding assay). Stimulates glucose-dependent insulin secretion in isolated human pancreatic islets. Reduces HIV-1 viral replication and shows cooperative effects when given in conjunction with VPAC1
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal.
Clairmont et al.
A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
Tsutsumi et al.
Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo.
Pan et al.
Macrophage resistance to HIV-1 infection is enhanced by the neuropeptides VIP and PACAP.
Temerozo et al.
PLoS ONE, 2013;8:67701
The citations listed below are publications that use Tocris products. Selected citations for Bay 55-9837 include:
Showing Results 1 - 2 of 2